PDCD1 and melanoma: In a study reporting on B cell dynamics in the peripheral blood of melanoma patients under anti-CTLA-4, anti-PD-1 or their combination, Das et al. reported that combined therapy correlated with a decline in circulating B cells coinciding with an increase in CD21lo B cells and plasmablasts detectable within a single cycle of therapy [110].